IMIO Raises $12M Seed to Expand Crop Residue Biologicals

Corn stalks left after harvest hold nutrients a grower has already paid to put into the field. IMIO has built a business around getting more of that value back into circulation, using a microbial treatment that helps crop residue break down. The Chicago agricultural biotechnology company is asking farmers to look at the material between seasons as part of the next crop's input budget.

IMIO announced $12M in funding on October 20, 2026, in a seed round led by Sofinnova Partners. Chipotle's Cultivate Next venture fund, Starshot Capital, Grow Together Salinas, Earth Foundry and Serra Ventures also participated. The investment supports a new Chicago headquarters, laboratory and biomanufacturing operations, putting production capacity behind the company's Re-Gen products for row crops and produce.

The financing connects a biological proposition with an ordinary purchasing decision: how much useful work can an input do on a particular farm? For a grower, recovering nutrients and making a field easier to prepare have value only when the benefits survive the costs and practical demands of using the product. IMIO's expansion takes that conversation from selected field trials toward a larger manufacturing and customer operation.

What the $12M funds at IMIO

The funding announcement hosted by Sofinnova Partners identifies facilities and biomanufacturing as the destination for the investment. IMIO has relocated from Vermont to Chicago, bringing the company closer to agricultural customers and the region's talent base. For a manufacturer supplying living organisms, a laboratory and a production operation sit directly inside the commercial promise: the product reaching the grower has to carry the capabilities demonstrated during development.

Charles Smith, IMIO's co-founder and CEO, built the company with co-founder Victoria Holden. The scientific work also reaches into industrial production: Neal Connors serves as fractional CTO, according to his AIChE biography. That mix matters because selecting useful microbes and manufacturing them consistently are related jobs with different demands. A good result in a field leaves the company with more work to do when the next order is larger.

Cultivate Next's involvement adds a food-system investor to the group. Chipotle had already publicly disclosed its IMIO investment in July, describing soil health and reduced reliance on conventional inputs as part of its interest. That earlier disclosure belongs in the financing history; adding an unspecified July check to the October round would manufacture a capital total the announcements do not establish.

How Re-Gen brings biology into the field

Re-Gen combines fungi, bacteria and yeast selected to support residue breakdown and nutrient availability. IMIO describes a manufacturing process in which strains are grown and tested individually, combined in precise ratios and freeze-dried. The grower activates the product with water before applying it to the material the microbes are intended to break down.

That placement is an important part of the proposition. Rather than asking a buyer to value soil biology in the abstract, IMIO points to a specific material and a specific job: help release nutrients from crop residue while making that residue easier to manage. The company offers versions for row crops and produce, where the practical benefit can show up differently in nutrient planning or the work of preparing the next planting.

Handling also belongs in the evaluation. IMIO's current product FAQ says application can use standard sprayers, irrigation systems or drones, following the label. It also tells growers to confirm compatibility before adding Re-Gen to a tank mix. Those details put a useful limit on an easy-to-use sales claim: an input has to fit the actual equipment, chemicals, water and schedule of the operation buying it.

The commercial attraction is straightforward. A concentrated, shelf-stable product gives the buyer a way to store the biology before activating it for use. The manufacturer's responsibility then travels with the package, from preserving microbial viability through shipment to giving the grower clear instructions for the day it goes onto a field.

Reading the field evidence without overselling it

IMIO reports that university and farm trials covering more than 10,000 Midwest acres in 2024 and 2025 produced an average corn yield increase of 11.9 bushels per acre. The company also reports nutrient credits of up to $120 per acre in row crops and tillage savings of up to $120 per acre in produce. These figures describe different outcomes in different production systems, with results dependent on field conditions and management.

A useful buyer would separate those benefits before assigning a return. Yield improvement, a possible adjustment to purchased fertilizer and an avoided tillage pass each have their own costs and timing. Combining the largest reported values into one universal payoff would erase the very differences a grower needs to understand before changing a nutrient plan.

There is also an earlier peer-reviewed Re-Gen study in Frontiers in Agronomy, published in June 2024. It examined fields on a Vermont dairy farm during 2022 and 2023 and reported improved yields. Its authors disclosed IMIO employment and ownership relationships. The paper adds a research record with methods a reader can inspect; its earlier setting and dataset should remain distinct from IMIO's later Midwest aggregate.

That distinction keeps the sales conversation useful. A grower can ask which crop, residue load, baseline practice and season produced a result, then decide whether those conditions resemble the acres under consideration. Manufacturing more Re-Gen expands access to that decision, while local evidence still determines how much confidence to put behind an order.

Nutrient recovery changes the purchasing conversation

Agricultural technology can enter a farm through several doors. DevCuration's reporting on TerraBlaster's soil-nutrient mapping concerns measuring what is in the field, while its coverage of Mafix's silicon fertilizer testing follows another route into crop inputs. IMIO's place in that conversation is nutrient recapture: making material already present do more useful work before the grower buys or applies additional inputs.

For founders selling into agriculture, that is a revealing commercial choice. The product has to explain its place alongside the farmer's existing practices, and the evidence has to be legible in the units the farm uses to make decisions. Acres, bushels, input costs and field-preparation work give the conversation a practical vocabulary. The usefulness of the biology becomes something the customer can compare with the rest of an operating plan.

IMIO's Chicago investment gives that approach a larger production base. As the company supplies more farms, each delivery carries a small sequence of responsibilities: a viable product, a workable application, an observation in the field and a decision about the following season. The financing is paying to repeat that sequence across more acres, with growers carrying the results into the next planting budget.